Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

Core Insights - Nexalin Technology, Inc. announced the publication of a peer-reviewed study demonstrating significant clinical improvement and sustained abstinence in a patient with gambling disorder and alcohol use disorder following treatment with its neurostimulation device [1][2]. Group 1: Study Findings - The study evaluated the safety and efficacy of Nexalin's 15 milliamp (mA) neurostimulation device, showing that the patient achieved complete abstinence from gambling and alcohol after 20 outpatient sessions over 10 days, with marked cognitive improvements and no adverse effects during a three-month follow-up [1][2]. - The authors concluded that Nexalin's device is a safe and effective potential treatment for comorbid gambling and alcohol use disorders, suggesting a neuroplastic mechanism that may involve deeper brain network modulation [2][3]. Group 2: Technology and Approval - Nexalin's neurostimulation system is approved in China for treating depression and insomnia, delivering a 15 mA current at 77.5 Hz for 40 minutes per session [3]. - The company emphasizes that its technology represents a breakthrough in non-invasive brain stimulation, aiming to modulate disturbed neural circuits related to mental health and addiction [4][5]. Group 3: Future Directions - The findings from the study warrant larger, controlled trials to further evaluate the efficacy of Nexalin's device in treating addiction comorbidities and other psychiatric disorders [4]. - The company is committed to advancing global research and expanding access to its drug-free therapy, highlighting the growing international recognition of its unique approach to whole brain stimulation [5].